Researcher Spotlight: Moah Soan, DVM, PhD ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI Jaime Peykoff Follicular Lymphoma Fellow Breakthrough therapies such as chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies have transformed the care of patients with follicular lymphoma…
Researcher Spotlight: Vignesh Shanmugam, MD BRIGHAM AND WOMEN’S HOSPITAL, INC. Tom Condon Family Fellow In many types of lymphoma, such as follicular lymphoma (FL), tumor cells are embedded in a rich microenvironment of non-malignant cells with which they regularly interact.…
Researcher Spotlight: Alberto Carturan, MD UNIVERSITY OF PENNSYLVANIA Jaime Peykoff Follicular Lymphoma Fellow Chimeric antigen receptor (CAR) T-cell therapies represent a groundbreaking advancement in the treatment of lymphoma. While CAR T-cell therapies have produced remarkable results for many patients, these…
Researcher Spotlight: Julie Erika Haydu, MD, PhD MASSACHUSETTS GENERAL HOSPITAL Runge Lymphoma Project Scholar Follicular lymphoma (FL) remains an incurable disease with current treatment options. Initial treatment of FL often involves the use of chemotherapy, and there are no approved…
Researcher Spotlight: Robert Kridel, MD, MPH, PhD UNIVERSITY HEALTH NETWORK, TORONTO Despite therapeutic advances that have transformed the treatment of follicular lymphoma (FL), the disease remains incurable for many patients. Using genomic profiling of tumor samples from large numbers of…
Researcher Spotlight: Arash Alizadeh, MD, PhD Stanford University Although many patients experience profound improvements in disease control with chimeric antigen receptor (CAR) T-cell therapies, not all people with follicular lymphoma (FL) treated with these agents will respond. Using cutting edge…
Researcher Spotlight: Wendy Béguelin, PhD WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY Follicular lymphoma (FL) is a clinically heterogenous disease. For some patients, tumors are slow growing and outcomes are favorable; others experience a high-risk, rapidly progressing disease that is associated…
Researcher Spotlight: Matthew Maurer, D.M.Sc MAYO CLINIC, ROCHESTER Follicular lymphoma (FL) is a heterogeneous disease characterized by episodes of relapse and transformation. Prognostic models exist that can be applied at diagnosis to predict how the disease will progress and what…
Researcher Spotlight: Patrizia Mondello, MD, PhD MAYO CLINIC, ROCHESTER In most cases, follicular lymphoma (FL) is a slow-growing cancer associated with favorable outcomes. Some patients experience a more aggressive disease course, though, characterized by early relapse and poor outcomes. Crosstalk…
Researcher Spotlight: Matthew Klairmont, MD NEW YORK UNIVERSITY SCHOOL OF MEDICINE In many cases, follicular lymphoma (FL) is an indolent and treatable B-cell lymphoma, and most patients live a normal lifespan. However, in a subset of patients, the disease can…